(77 days)
The Right Angle Laser Fibers and Optilase Lasers are indicated for a wide variety of surgical uses including incision, excision, resection, vaporization, ablation, coagulation and hemostasis. In addition, they are indicated for coagulation of soft tissue for prostatectomy in the treatment of benign prostatic hyperplasia (BPH).
The Optilase laser systems are continuous wave Nd: YAG energy sources equipped with an aiming beam, adjustable power output, and a fiber optic connector.
The Right Anale Laser Fibers are fiber optic Nd:YAG energy delivery systems consisting of : a three meter length of buffered quartz fiber, a tip which allows delivery of laser energy, and a fiber optic connector.
The provided text does not contain information about acceptance criteria and a study proving a device meets those criteria in the way a medical device submission for AI/ML would. The document describes a 510(k) submission for laser fibers and laser systems for BPH treatment from 1997.
Therefore, I cannot fulfill your request with the given input. The categories you listed (e.g., acceptance criteria table, sample size for test set, number of experts for ground truth, MRMC study, standalone performance, training set details) are typical for AI/ML device evaluations, which are not detailed in this historical 510(k) summary.
The document states:
- No nonclinical tests were submitted.
- A limited clinical study was undertaken to provide information related to Visual Laser Ablation of the Prostate (VLAP) with 60 watts of laser power. These data were compared to data obtained from an earlier study in which VLAP at 40 watts of laser power was compared to TURP.
- Conclusions: "The results of the comparative data submitted... demonstrate that VLAP, whether it be performed at 40 watt treatment parameters, is a viable alternative to TURP."
This indicates a clinical comparison study, but it does not specify acceptance criteria, test set details, ground truth methods, or other elements pertinent to AI/ML device validation.
{0}------------------------------------------------
APR 21 1997
Image /page/0/Picture/1 description: The image shows the word "Trimedyne" in a bold, sans-serif font. Below the word is a logo consisting of three stacked, stylized arrow shapes. The arrows are pointing to the right and are arranged in a descending order of size from top to bottom.
Summary of 510(k) Safety and Effectiveness Information
Trimedyne® Right Angle Laser Fibers and Optilase® Lasers for the Treatment of BPH at 60 watts of Laser Power
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
| I. | Submitter Information: | Trimedyne, Inc.P.O. Box 57001Irvine, CA 92619-7001714/559-5300714/559-1330 |
|---|---|---|
| Contact Person: | Susan H. GambleDirector, Regulatory Affairs & Quality Assurance | |
| Summary Date: | February 3, 1997 |
ll. Device Name
Optilase® Model 1000 Nd:YAG Laser System Proprietary:
Optilase® Model 4000 Nd:YAG Laser System
Optilase® PL100 Model 1000-100 Nd:YAG Laser System
UroGold™ Right Angle Laser Fibers
UroMax™ Right Angle Laser Fibers
Additional proprietary names may be used for other Right Angle Laser Fiber configurations.
Common: Laser-powered Instrument
Laser Fiber
Classification: Nd:YAG Laser System
Accessory to Laser-powered Instrument - Not Classified
III. Predicate Device
The predicate devices are those cleared under 510(k) K954597.
IV. Device Description
The Optilase laser systems are continuous wave Nd: YAG energy sources equipped with an aiming beam, adjustable power output, and a fiber optic connector.
The Right Anale Laser Fibers are fiber optic Nd:YAG energy delivery systems consisting of : a three meter length of buffered quartz fiber, a tip which allows delivery of laser energy, and a fiber optic connector.
TRIMEDYNE, INC. 2801 BARRANCA ROAD, IRVINE, CA 92714 714 559-5300, FAX 714 559-1330 800 733-5273
{1}------------------------------------------------
V. Intended Use
The Right Angle Laser Fibers and Optilase Lasers are indicated for a wide variety of surgical uses including incision, excision, resection, vaporization, ablation, coagulation and hemostasis. In addition, they are indicated for coagulation of soft tissue for prostatectomy in the treatment of benign prostatic hyperplasia (BPH).
VI. Technological Characteristics
There are no technological differences between these devices and those cleared under K954597.
VII. Nonclinical Tests
No nonclinical tests were submitted in this Premarket Notification.
VIII. Clinical Tests
A limited clinical study was undertaken to provide information related to Visual Laser Ablation of the Prostate (VLAP) with 60 watts of laser power. These data were compared to data obtained from an earlier study in which VLAP at 40 watts of laser power was compared to TURP.
IX. Conclusions Drawn from Testing
The results of the comparative data submitted in this Premarket Notification demonstrate that VLAP, whether it be performed at 40 watt treatment parameters, is a viable alternative to TURP.
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.